Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors

Last updated: February 5, 2025
Sponsor: Matteo Cameli
Overall Status: Completed

Phase

N/A

Condition

Congestive Heart Failure

Chest Pain

Heart Failure

Treatment

Sodium-GLucose coTransporter-2 inhibitors

Clinical Study ID

NCT05344963
DISCOVER SGLT2i
  • Ages > 18
  • All Genders

Study Summary

It is an observational, cohort, prospective, multicentre, Italian, non-profit study, with the aim of evaluating the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with SGLT2i Dapagliflozin and Empagliflozin.

Participation in the study will last for approximately 18 months, and a total of 300 patients will be enrolled at the various Research Centers.

The enrolled patients will undergo a first evaluation in which the anamnestic, clinical and conventional and advanced echocardiographic data will be recorded. At this point, the patient will start SGLT2i.

After starting SGLT2i, a second evaluation will be carried out with a cardiological visit at 6 months, in which the same data listed above will then be recorded.

At the end of the evaluation, the clinical follow-up will be continued for the duration of 1 year, in number and frequency according to clinical indication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Providing informed consent prior to any specific study procedure

  2. Female or male outpatient patients > 18 years

  3. Have heart failure and left ventricular ejection fraction <= 40%, according to theESC definition

  4. Already on therapy with an angiotensin converting enzyme (ACE) inhibitor orsacubitril / valsartan, a beta-blocker and mineralocorticoid receptor antagonist (MRA) and be initiated for treatment with SGLT2i for therapy optimization

Exclusion

Exclusion Criteria:

  1. Involvement in study planning and / or conducting (applies to both investigatorstaff and study site staff)

  2. Age <18 years

  3. For women only - ongoing pregnancy (confirmed with positive pregnancy test)

  4. For women only - breastfeeding

  5. Poor quality of echocardiographic images which compromises a correct speckletracking analysis

  6. Failure to sign informed consent.

  7. Previous treatment with SGLT2i.

Study Design

Total Participants: 503
Treatment Group(s): 1
Primary Treatment: Sodium-GLucose coTransporter-2 inhibitors
Phase:
Study Start date:
April 01, 2022
Estimated Completion Date:
June 01, 2024

Connect with a study center

  • UOC Diagnostica Cardiovascolare, AOU Senese Policlinico Le Scotte

    Siena, 53100
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.